Position history for CITADEL ADVISORS LLC's holdings in BRIDGEBIO ONCOLOGY THERAPEUT
CITADEL ADVISORS LLC holds 2.5M shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT), worth $22.6M as of 2026-Q1. The position was decreased (-0.1% shares). BBOT represents 0.0% of CITADEL ADVISORS LLC's portfolio.
Current Value
$22.6M
Current Shares
2.5M
Total Value Change
-$6.8M
Total Shares Change
-9,379
Other major holders of BBOT: WELLINGTON MANAGEMENT GROUP LLP, Alphabet Inc., BlackRock, Inc.
Decreased |
| 2.5M |
-0.1% |
| $22.6M |
| 0.0% |
| $9.74 |
0 |
| 2025-Q4 | Decreased | 2.5M | -0.3% | $31.7M | 0.0% | $12.37 | 0 |
| 2025-Q3 | New | 2.5M | - | $29.4M | 0.0% | $11.47 | 40 |